Bristol Myers Squibb Company is a global biopharmaceutical company, headquartered in New York City with 30,000 employees globally. Our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Bristol Myers Squibb focuses its research efforts in the areas of oncology, hematology, immunology, cardiovascular – and fibrotic diseases; all of which are areas of high, unmet medical need. We are proud of the advancements we have made in these particular disease areas, and we are dedicated to helping patients prevail over serious diseases through our diverse and promising pipelines and new scientific platforms.
Bristol Myers Squibb is a differentiated company, led by our unique biopharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm.
From 2008 to 2017, Bristol Myers Squibb invested directly in seven different Danish companies (mostly biotech companies), equaling a total amount of more than USD 1.7 billion (approximately 12 billion DKK), making Denmark the country that attracted the most investments outside the US during 2008-2017, both in numbers of investments and in monetary terms.
Bristol Myers Squibb has engaged in very significant partnerships and collaborations throughout the years, contributing to the thriving Danish life science industry. The investments made from 2015 to 2017 make Bristol Myers Squibb one of the biggest foreign investors in Denmark overall.
In November 2019, Bristol Myers Squibb completed the acquisition of the Celgene Corporation. The acquisition valued at 90 billion USD is one of the largest acquisitions in the history of the pharmaceutical industry. The combination of the leading science, innovative medicines and talent of both Bristol Myers Squibb and Celgene created a leading global biopharma company that continues to deliver highly advanced and innovative medicines for patients with serious diseases.